Articles From: Eaton Vance Tax-Managed Global Diversified Equity Income Fund Report Of Earnings to FDA Approves Exact Sciences' Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test


--Webcast and conference call today at 8:30 a.m. EDT--
Sign-up for Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update investment picks
CAESAREA, Israel, Aug.
Sign-up for Elbit Vision Systems Announces Second Quarter 2014 Results investment picks
2014/8/12
Adjusted EBITDA Increased to Approximately $553,000 and Quarter Margins Reach 88% on $6.9 Million of Revenue OKLAHOMA CITY , Aug.
Sign-up for Elephant Talk Reports Second Quarter Financial Results investment picks
SAO JOSE DOS CAMPOS, Brazil , Aug.
Sign-up for Embraer's Legacy 500 Executive Jet awarded Brazilian certification investment picks
HOUSTON , Aug.
Sign-up for Endeavour to Present at EnerCom's The Oil and Gas Conference investment picks
Enphase Energy (NASDAQ: ENPH) announced today the renewal of its strategic inverter agreement with an affiliate of Vivint Solar, Inc., a leading provider of residential solar energy systems in the United States.
Sign-up for Enphase Energy and Vivint Solar Sign Three-Year Strategic Agreement investment picks
MIGDAL HA'EMEQ, Israel, Aug.
Sign-up for Enzymotec Ltd. Announces Initiation of a Clinical Study on Autism Spectrum Disorder investment picks
KANSAS CITY, Kan., Aug.
Sign-up for Epiq Systems Announces Appointment of Douglas M. Gaston to Its Board of Directors investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas.
Sign-up for Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology investment picks
2014/8/12
LONG BEACH, Calif.
Sign-up for Epson Exhibition Watercolor Paper Textured Wins Best Fine-art Paper in 2014 Hot One Awards investment picks
EQT Corporation’s (NYSE: EQT) chairman, president and CEO, David Porges, is scheduled to present at EnerCom’s Oil & Gas Conference 2014 on Tuesday, August 19 --
Sign-up for EQT to Present at EnerCom’s Oil & Gas Conference 2014 investment picks
The Rosen Law Firm, P.A. is investigating the Board of Directors of Fortegra Financial Corporation (NYSE:FRF) for possible breaches of fiduciary duties and other violations of law by failing to adequately shop Fortegra to maximize shareholder value before entering into a merger agreement with Tiptree Financial Inc. (NASDAQ: TIPT). If you would like to join the action, visit the website at http://rosenlegal.com/cases-332.html or please call Phillip Kim, Esq.
Sign-up for EQUITY ALERT: The Rosen Law Firm Announces Investigation of Fortegra Financial Corporation (FRF) Concerning the Proposed Acquisition by Tiptree Financial Inc. (TIPT) investment picks
Equity One, Inc. (NYSE:EQY), an owner, developer, and operator of shopping centers, announced today that its Board of Directors has declared a cash dividend of $0.22 per share of its common stock for the quarter ending September 30, 2014, payable on September 30, 2014 to stockholders of record on September 16, 2014.
Sign-up for Equity One Declares $0.22 per Share Dividend for Third Quarter of 2014 investment picks
Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2014.
Sign-up for Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2014 Financial Results investment picks
2014/8/12
By Tommy Stubbington Henkel falls as it warns of Ukraine impact -Tommy Stubbington ; 415-439-6400; AskNewswires@dowjones.com European stock markets drifted lower Tuesday as the previous session's strong rally fizzled out.
Sign-up for European markets drift lower as geo-worries fade investment picks
2014/8/12
NANJING , China , Aug.
Sign-up for Ever-Glory Schedules Second Quarter 2014 Earnings Release and Conference Call investment picks
LANCASTER, Ohio, Aug.
Sign-up for EveryWare Global to Host Second Quarter 2014 Earnings Conference Call investment picks
SOLANA BEACH, Calif., Aug.
Sign-up for Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001 investment picks
The Board of Directors for Exelis ( NYSE: XLS ) has declared a cash dividend of $0.1033 per share for the third quarter of 2014.
Sign-up for Exelis board approves $0.1033 per share dividend for the third quarter of 2014 investment picks
NORTH HUNTINGDON, Pa., Aug.
Sign-up for ExOne Appoints METOS vos as Independent Sales Representative in Eastern European Countries investment picks
SALT LAKE CITY , Aug.
Sign-up for Extra Space Storage Celebrates 10 Years on the New York Stock Exchange investment picks
2014/8/12
FAB Universal (NYSE MKT: FU) (“FAB” or the “Company”), a worldwide distributor of digital media and entertainment, today announced the completion of the investigation of allegations raised by short sellers and repeated in civil complaints.
Sign-up for FAB Provides Update on Internal Investigation and NYSE MKT Delisting Proceedings investment picks
2014/8/12
HARMAN announced today that its Aha Radio service has integrated Radio Disney, the #1 radio network for kids, tweens and families, into today’s two million Aha-enabled vehicles.
Sign-up for Families Rejoice! Aha Radio Integrates Radio Disney for Best Near and Far Road Trips Yet investment picks
First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment SAN DIEGO, Aug.
Sign-up for Fate Therapeutics Reports Second Quarter 2014 Financial Results investment picks
FCB Financial Holdings, Inc. (NYSE:FCB) (the "Company") today reported second quarter 2014 net income of $9.2 million, or $0.26 per diluted share, and core net income of $7.4 million, or $0.21 per diluted share.
Sign-up for FCB Financial Holdings, Inc. Reports Second Quarter Net Income of $9.2 Million, or $0.26 Per Diluted Share, Up 114% Year Over Year investment picks
First time in history a technology receives FDA approval and proposed national coverage by CMS on the same day Screening test detects 92% of colorectal cancer MADISON, Wis.
Sign-up for FDA Approves Exact Sciences' Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Eaton Vance Tax-Managed Global Diversified Equity Income Fund Report Of Earnings to FDA Approves Exact Sciences' Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices